Replies to post #76406 on PharmaCyte Biotech Inc (PMCB)

[frosr6]

They sure did!

Quote:
“TGen receives $2.5 million SU2C grant for new pancreatic cancer clinical trial”

I wonder why Dr. Von Hof didn’t pick ciab. Unlike investors he has no faith I guess.

Dr. Daniel Von Hoff, TGen Distinguished Professor and Physician-In-Chief, will lead a pancreatic cancer clinical trial that will pair an immunotherapy drug called pembrolizumab (trademarked as Keytruda®), with a Vitamin D Receptor (VDR) agonist called paricalcitol (trademarked as Zemplar®).

https://www.eurekalert.org/pub_releases/2017-10/ttgr-tr101217.php